Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H13ClNO3.Na.2H2O |
Molecular Weight | 349.742 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].CN1C(CC([O-])=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2
InChI
InChIKey=ZJXLSCXDGPDZOL-UHFFFAOYSA-M
InChI=1S/C15H14ClNO3.Na.2H2O/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10;;;/h3-7H,8H2,1-2H3,(H,18,19);;2*1H2/q;+1;;/p-1
Zomepirac Sodium (Zomax) is a pyrrole-acetic acid structurally related to tolmetin sodium. Zomepirac is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate. Zomepirac was approved by the Food and Drug Administration for marketing in the United States as an analgesic. It was indicated for all forms of mild to moderately severe pain, and was being promoted as a "comprehensive, non-addicting analgesic." Later Zomepirac was found to be associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096674 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7018870 |
15.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOMAX Approved UseZOMAX is indicated for all forms of mild to moderately severe pain. Launch Date1979 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.94 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.42 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.47 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1102.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
494.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
232.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7357796 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOMEPIRAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 6 times / day multiple, oral Dose: 100 mg, 6 times / day Route: oral Route: multiple Dose: 100 mg, 6 times / day Sources: |
unhealthy, 28 years n = 1 Health Status: unhealthy Age Group: 28 years Sex: F Population Size: 1 Sources: |
Disc. AE: Renal insufficiency... AEs leading to discontinuation/dose reduction: Renal insufficiency (1 patient) Sources: |
300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 36-72 years n = 2 Health Status: unhealthy Age Group: 36-72 years Sex: F Population Size: 2 Sources: |
Disc. AE: Renal insufficiency... AEs leading to discontinuation/dose reduction: Renal insufficiency (2 patients) Sources: |
800 mg 1 times / day single, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: single Dose: 800 mg, 1 times / day Sources: |
unhealthy n = 10 Health Status: unhealthy Condition: opioid abuse Population Size: 10 Sources: |
Other AEs: Backache, Nausea... Other AEs: Backache (2 patients) Sources: Nausea (2 patients) Churning of stomach (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Renal insufficiency | 1 patient Disc. AE |
100 mg 6 times / day multiple, oral Dose: 100 mg, 6 times / day Route: oral Route: multiple Dose: 100 mg, 6 times / day Sources: |
unhealthy, 28 years n = 1 Health Status: unhealthy Age Group: 28 years Sex: F Population Size: 1 Sources: |
Renal insufficiency | 2 patients Disc. AE |
300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 36-72 years n = 2 Health Status: unhealthy Age Group: 36-72 years Sex: F Population Size: 2 Sources: |
Backache | 2 patients | 800 mg 1 times / day single, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: single Dose: 800 mg, 1 times / day Sources: |
unhealthy n = 10 Health Status: unhealthy Condition: opioid abuse Population Size: 10 Sources: |
Churning of stomach | 2 patients | 800 mg 1 times / day single, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: single Dose: 800 mg, 1 times / day Sources: |
unhealthy n = 10 Health Status: unhealthy Condition: opioid abuse Population Size: 10 Sources: |
Nausea | 2 patients | 800 mg 1 times / day single, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: single Dose: 800 mg, 1 times / day Sources: |
unhealthy n = 10 Health Status: unhealthy Condition: opioid abuse Population Size: 10 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 6.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 3.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 3.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 3.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 3.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16251255/ Page: 6.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Zomepirac, interstitial nephritis, and renal failure. | 1982 Sep |
|
Nonoliguric renal failure associated with zomepirac. | 1983 Apr 1 |
|
Zomepirac-related acute renal failure. | 1983 Jan |
|
Effect of zomepirac on experimental coronary artery thrombosis and ischemic myocardial injury in the conscious dog. | 1983 Mar-Apr |
|
Severe coronary spasm during zomepirac-induced allergic reaction. | 1984 Jul |
|
Zomepirac-induced anaphylactic shock: an under-reported phenomenon. | 1985 Oct |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. | 2001 Nov 21 |
|
India ink staining after sodium dodecyl sulfate polyacrylamide gel electrophoresis and in conjunction with Western blots for peptide mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | 2002 |
|
Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse. | 2002 Jan |
|
Differential binding mode of diverse cyclooxygenase inhibitors. | 2002 Mar |
|
Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. | 2003 Nov |
|
In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. | 2005 Nov |
|
I almost crossed over. | 2005 Oct |
|
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. | 2005 Oct 4 |
|
Predicting the pharmacokinetics of acyl glucuronides and their parent compounds in disease states. | 2006 Feb |
|
Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems. | 2006 Jan |
|
Effect of drug utilization reviews on the quality of in-hospital prescribing: a quasi-experimental study. | 2006 Mar 14 |
|
Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. | 2007 Jun |
|
Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update. | 2007 Mar 15 |
|
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009 Dec 2 |
|
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. | 2009 Mar 16 |
|
Entrapment of ketorolac tromethamine in polymeric vehicle for controlled drug delivery. | 2009 Nov |
|
Neuroprotective effects of zonisamide target astrocyte. | 2010 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7018870
The oral dose of zomepirac for mild to moderately
severe pain is 50-100 mg every four to six hours. In
acute moderate to severe pain in adults, a 100-mg
dose would be reasonable initial therapy. In chronic
pain situations, the 50-mg dose may be as effective in
some patients as the 100-mg dose. Doses of more
than 100 mg are not recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6133523
Zomepirac failed to displace tritiated etorphine significantly at concentrations up to 200 umol/l. It was active (3-7 X 10(-5) mol/l) on both the electrically stimulated guinea pig ileum and mouse vas deferens but was less efficacious than morphine; these effects were not reversed by narcotic antagonists.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05193MIG
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
58331
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT002461
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
C62001
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
100000087906
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
757379
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
23663418
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
m1270
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID60214282
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL19490
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
Y0185WZ209
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY | |||
|
64092-49-5
Created by
admin on Fri Dec 15 15:49:35 GMT 2023 , Edited by admin on Fri Dec 15 15:49:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD